Targeting bacterial weak spots – vital cystic fibrosis research supported by AJN Steelstock.
Antimicrobial resistance is a hot health-news story and it’s one followed with interest by people with cystic fibrosis and their families. The development of new antibiotics could make a lifechanging difference to them.
The Cystic Fibrosis Trust has formed a partnership with the University of Cambridge, known as the Innovation Hub, to fund world-leading research on lung health for people with cystic fibrosis (CF). One of the programmes within it is to design new antibiotics to keep the lungs of people with CF healthier for longer and AJN Steelstock is delighted to be supporting the Innovation Hub, as part of our continued commitment to cystic fibrosis research.
Scientists at the University of Cambridge are studying the genetics of two particularly persistent bacteria present in the lungs of people with CF. By studying every part of the genetic code of these bacteria in detail they hope to identify new ‘weak spots’ to target with a new design of antibiotics. The new antibiotics could be used to slow down the lung damage these infections cause, giving people with cystic fibrosis a healthier, longer life.
Scientists at the Innovation Hub are making good progress and AJN Steelstock is committed to supporting this vital research to develop lifechanging treatments for people with cystic fibrosis, and ultimately beating this cruel condition for good.
“The work produced by the Innovation Hub is outstanding. It’s already achieved remarkable things towards treatments for infection. Each part of the Innovation Hub programme is being conducted by world-leading scientists, doing cutting-edge research” explained Dr Janet Allen, Director of Strategic Innovation at the Cystic Fibrosis Trust.
“It is well on track to deliver research that will significantly improve the lives of people with cystic fibrosis”.